A Retreat In Medical Devices
Just a couple of years ago, combining medical device and pharmaceutical businesses made sense. Managed care would reign in the profitability of drug businesses, bringing it more in line with medical devices, and a bundled offering would appeal to bigger customers. But managed care's bark has been worse than its bite. With drug profits on the rise, pharmaceutical companies are bailing out of the medical device business in record numbers.
You may also be interested in...
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.
Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.